Lysostaphin-resistant variants of Staphylococcus aureus demonstrate reduced fitness in vitro and in vivo

Antimicrobial Agents and Chemotherapy

Volumn 51, Issue 2, 2007, Pages 475-482

  Kusuma, Caroline ^a,b   Jadanova, Anna ^a,c   Chanturiya, Tanya ^a,d   Kokai Kun, John F ^a  

^a Biosynexus Incorporated   (United States)

^b AFG Biosolutions   (United States)

^c HOFSTRA UNIVERSITY   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL PROTEIN; BETA LACTAM ANTIBIOTIC; FEMA PROTEIN; GLYCINE; LYSOSTAPHIN; PEPTIDOGLYCAN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; BACTERIAL GROWTH; BACTERIAL STRAIN; BACTERIAL VIRULENCE; COCULTURE; CONTROLLED STUDY; FEMA GENE; FEMALE; GENE MUTATION; GROWTH RATE; IN VITRO STUDY; IN VIVO STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MOUSE; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; STRAIN DIFFERENCE; TEMPERATURE DEPENDENCE; WILD TYPE;

ANIMALS; BACTERIAL PROTEINS; DRUG RESISTANCE, MICROBIAL; LYSOSTAPHIN; MICE; MUTATION; STAPHYLOCOCCUS AUREUS;

EID: 33846623697     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00786-06     Document Type: Article

References (41)

1. Andersson, D. I., and B. R. Levin. 1999. The biological cost of antibiotic resistance. Curr. Opin. Microbiol. 2:489-493.
2. Antonio, M., N. McFerran, and M. J. Pallen. 2002. Mutations affecting the Rossman fold of isoleucyl-tRNA synthetase are correlated with low-level mupirocin resistance in Staphylococcus aureus. Antimicrob. Agents Chemother. 46:438-442.
3. Bohach, G. A., and T. J. Foster. 2000. Staphylococcus aureus exotoxins, p. 367-378. In V. A. Fischetti, R. P. Novick, J. J. Ferretti, D. A. Portnoy, and J. I. Rood (ed.), Gram-positive pathogens. ASM Press, Washington, DC.
4. Centers for Disease Control and Prevention. 2002. Staphylococcus aureus resistant to vancomycin - United States, 2002. Morb. Mortal. Wkly. Rep. 51:565-567.
5. Climo, M., K. Ehlert, and G. Archer. 2001. Mechanism and suppression of lysostaphin resistance in oxacillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 45:1431-1437.
6. Climo, M. W., R. L. Patron, B. P. Goldstein, and G. L. Archer. 1998. Lysostaphin treatment of experimental methicillin-resistant Staphylococcus aureus aortic valve endocarditis. Antimicrob. Agents Chemother. 42:1355-1360.
7. Dajcs, J. J., E. B. Hume, J. M. Moreau, A. R. Caballero, B. M. Cannon, and R. J. O'Callaghan. 2000. Lysostaphin treatment of methicillin-resistant Staphylococcus aureus keratitis in the rabbit. Investig. Opthalmol. Vis. Sci. 41:1432-1437.
8. DeHart, H., H. Heath, L. Heath, P. LeBlanc, and G. Sloan. 1995. The lysostaphin endopeptidase resistance gene (epr) specifies modification of peptidoglycan cross bridges in Staphylococcus simulans and Staphylococcus aureus. Appl. Environ. Microbiol. 61:1475-1479.
9. Ehlert, K., W. Schroder, and H. Labischinski. 1997. Specificities of FemA and FemB for different glycine residues: FemB cannot substitute for FemA in staphylococcal peptidoglycan pentaglycine side chain formation. J. Bacteriol. 179:7573-7576.
10. Ehlert, K., M. Tschierske, C. Mori, W. Schroder, and B. Berger-Bachi. 2000. Site-specific serine incorporation by Lif and Epr into positions 3 and 5 of the staphylococcal peptidoglycan interpeptide bridge. J. Bacteriol. 182:2635-2638.
11. Ender, M., N. McCallum, R. Adhikari, and B. Berger-Bachi. 2004. Fitness cost of SCCmec and methicillin resistance levels in Staphylococcus aureus. Antimicrob. Agents Chemother. 48:2295-2297.
12. Grundling, A., D. M. Missiakas, and O. Schneewind. 2006. Staphylococcus aureus mutants with increased lysostaphin resistance. J. Bacteriol. 188:6286-6297.
13. Guignard, B., J. M. Entenza, and P. Moreillon. 2005. β-Lactams against methicillin-resistant Staphylococcus aureus. Curr. Opin. Pharmacol. 5:479-489.
14. Heath, L. S., S. R. Gargis, S. R. Smithberg, H. P. Johnson, H. E. Heath, P. A. LeBlanc, and G. L. Sloan. 2005. Plasmid-specific FemABX-like immunity factor in Staphylococcus sciuri DD 4747. FEMS Microbiol. Lett. 249:227-231.
15. Hurdle, J. G., A. J. O'Neill, E. Ingham, C. Fishwick, and I. Chopra. 2004. Analysis of mupirocin resistance and fitness in Staphylococcus aureus by molecular genetic and structural modeling techniques. Antimicrob. Agents Chemother. 48:4366-4376.
16. Kiri, N., G. Archer, and M. Climo. 2002. Combinations of lysostaphin with β-lactams are synergistic against oxacillin-resistant Staphylococcus epidermidis. Antimicrob. Agents Chemother. 46:2017-2020.
17. Kline, S. A., J. de la Harpe, and P. Blackburn. 1994. A colorimetric microliter plate assay for lysostaphin using a hexaglycine substrate. Anal. Biochem. 217:329-331.
18. Kokai-Kun, J. F., S. M. Walsh, T. Chanturiya, and J. J. Mond. 2003. Lysostaphin cream eradicates Staphylococcus aureus nasal colonization in a cotton rat model. Antimicrob. Agents Chemother. 47:1589-1597.
19. Kusuma, C. M., and J. F. Kokai-Kun. 2005. Comparison of four methods for determining lysostaphin susceptibility of various strains of Staphylococcus aureus. Antimicrob. Agents Chemother. 49:3256-3263.
20. Labschinski, H., K. Ehlert, and B. Berger-Bachi. 1998. The targeting factors necessary for expression of methicillin resistance in staphylococci. J. Antimicrob. Chemother. 41:581-584.
21. Ling, B., and B. Berger-Bachi. 1998. Increased overall antibiotic susceptibility in Staphylococcus aureus femAB null mutants. Antimicrob. Agents Chemother. 42:936-938.
22. Lowy, F. D. 2003. Antimicrobial resistance: the example of Staphylococcus aureus. J. Clin. Investig. 111:1265-1273.
23. Maisnier-Patin, S., and D. I. Andersson. 2004. Adaptation to the deleterious effects of antimicrobial drug resistance mutations by compensatory mutations. Res. Microbiol. 155:360-369.
24. Mani, N., P. Tobin, and R. K. Jayaswal. 1993. Isolation and characterization of autolysis-defective mutants of Staphylococcus aureus created by Tn917-lacZ mutagenesis. J. Bacteriol. 175:1493-1499.
25. Massey, R. C., A. Buckling, and S. J. Peacock. 2001. Phenotypic switching of antibiotic resistance circumvents permanent costs in Staphylococcus aureus. Curr. Biol. 11:1810-1814.
26. Mierau, I., P. Leij, I. van Swam, B. Blommestein, E. Floris, J. J. Mond, and E. J. Smid. 2005. Industrial-scale production and purification of a heterologous protein in Lactococcus lactis using the nisin-controlled gene expression system NICE: the case of lysostaphin. Microb. Cell Fact. 4:1-9.
27. Murakami, K., and A. Tomasz. 1989. Involvement of multiple genetic determinants in high-level methicillin resistance in Staphylococcus aureus. J. Bacteriol. 171:874-879.
28. Patron, R. L., M. W. Climo, B. P. Goldstein, and G. L. Archer. 1999. Lysostaphin treatment of experimental aortic valve endocarditis caused by a Staphylococcus aureus isolates with reduced susceptibility to vancomycin. Antimicrob. Agents Chemother. 43:1754-1755.
29. Proctor, R. A. 2000. Respiration and small colony variants of Staphylococcus aureus, p. 345-350. In V. A. Fischetti, R. P. Novick, J. J. Ferretti, D. A. Portnoy, and J. I. Rood (ed.), Gram-positive pathogens. ASM Press, Washington, DC.
30. Robinson, J. M., J. K. Hardman, and G. L. Sloan. 1979. Relationship between lysostaphin endopeptidase production and cell wall composition in Staphylococcus staphylolyticus. J. Bacteriol. 137:1158-1168.
31. Rohrer, S., and B. Berger-Bachi. 2003. FemABX peptidyl transferase: a link between branched-chain cell wall peptide formation and β-lactam resistance in gram-positive cocci. Antimicrob. Agents Chemother. 47:837-846.
32. Rohrer, S., K. Ehlert, M. Tscierske, H. Labschinski, and B. Berger-Bachi. 1999. The essential Staphylococcus aureus gene fmhB is involved in the first step of peptidoglycan pentaglycine interpeptide formation. Proc. Natl. Acad. Sci. USA 96:9351-9356.
33. Schneewind, O. A., A. Fowler, and K. F. Faull. 1995. Structure of the cell wall anchor of surface proteins in Staphylococcus aureus. Science 268:103-106.
34. Shopsin, B., M. Gomez, S. O. Montgomery, D. H. Smith, M. Waddington, D. E. Dodge, D. A. Bost, M. Riehman, S. Naidich, and B. N. Kreiswirth. 1999. Evaluation of protein A gene polymorphic region DNA sequencing for typing of Staphylococcus aureus strains. J. Clin. Microbiol. 37:3556-3563.
35. Smith, T. L., M. L. Pearson, K. R. Wilcox, C. Cruz, M. V. Lancaster, B. Robinson-Dunn, F. C. Tenover, M. J. Zervos, J. D. Band, E. White, and W. R. Jarvis. 1999. Emergence of vancomycin resistance in Staphylococcus aureus. N. Engl. J. Med. 340:493-501.
36. Stranden, A., K. Ehlert, H. Labischinski, and B. Berger-Bachi. 1997. Cell wall monoglycine cross-bridges and methicillin hypersusceptibility in a femAB null mutant of methicillin-resistant Staphylococcus aureus. J. Bacteriol. 179:9-16.
37. Sugai, M., T. Fujiwara, K. Ohta, H. Komatsuzawa, M. Ohara, and H. Suginaka. 1997. epr, which encodes glycylglycine edopeptidase resistance, is homologous to femAB and affects serine content of peptidoglycan cross bridges in Staphylococcus capitis and Staphylococcus aureus. J. Bacteriol. 179:4311-4318.
38. Thumm, G., and F. Gotz. 1997. Studies on prolysostaphin processing and characterization of the lysostaphin immunity factor (Lif) of Staphylococcus simulans biovar staphylolyticus. Mol. Microbiol. 23:1251-1265.
39. Ton-That, H., H. Labschinski, B. Berger-Bachi, and O. Schneewind. 1998. Anchor structure of staphylococcal surface proteins. J. Biol. Chem. 273:29143-29149.
40. Wu, J. A., C. Kusuma, J. J. Mond, and J. F. Kokai-Kun. 2003. Lysostaphin disrupts Staphylococcus aureus and Staphylococcus epidermidis biofilms on artificial surfaces. Antimicrob. Agents Chemother. 47:3407-3414.
41. Zygmunt, W. A., and P. A. Tavormina. 1972. Lysostaphin: model for a specific enzymatic approach to infectious disease. Prog. Drug Res. 16:309-333.